Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?
Open Access
- 5 July 2015
- journal article
- review article
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 370 (1672) , 20140184
Abstract
The long-term replacement therapy with the dopamine (DA) precursor 3,4-dihydroxy-l-phenylalanine (L-DOPA) is a milestone in the treatment of Parkinson's disease (PD). Although this drug precursor can be metabolized into the active neurotransmitter DA throughout the brain, its therapeutic benefit is due to restoring extracellular DA levels within the dorsal striatum, which lacks endogenous DA as a consequence of the neurodegenerative process induced by the disease. In the early phases of PD, L-DOPA treatment is able to restore both long-term depression (LTD) and long-term potentiation (LTP), two major forms of corticostriatal synaptic plasticity that are altered by dopaminergic denervation. However, unlike physiological DA transmission, this therapeutic approach in the advanced phase of the disease leads to abnormal peaks of DA, non-synaptically released, which are supposed to trigger behavioural sensitization, namely L-DOPA-induced dyskinesia. This condition is characterized by a loss of synaptic depotentiation, an inability to reverse previously induced LTP. In the advanced stages of PD, L-DOPA can also induce non-motor fluctuations with cognitive dysfunction and neuropsychiatric symptoms such as compulsive behaviours and impulse control disorders. Although the mechanisms underlying the role of L-DOPA in both motor and behavioural symptoms are still incompletely understood, recent data from electrophysiological and imaging studies have increased our understanding of the function of the brain areas involved and of the mechanisms implicated in both therapeutic and adverse actions of L-DOPA in PD patients.Keywords
This publication has 109 references indexed in Scilit:
- Dopamine restores reward prediction errors in old ageNature Neuroscience, 2013
- The Spike-Timing Dependence of PlasticityNeuron, 2012
- Dosage-dependent non-linear effect ofl-dopa on human motor cortex plasticityThe Journal of Physiology, 2010
- Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatmentMovement Disorders, 2010
- The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbensTrends in Neurosciences, 2010
- Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatumNeuropharmacology, 2010
- Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Neurobiological Mechanisms of Placebo ResponsesAnnals of the New York Academy of Sciences, 2009
- Dichotomous Dopaminergic Control of Striatal Synaptic PlasticityScience, 2008
- Dopaminergic modulation of the persistence of one-trial hippocampus-dependent memoryLearning & Memory, 2006